WOBURN, Mass.--(BUSINESS WIRE)--Cambria Biosciences, a biopharmaceutical company focused on brain disorders, today presented new research findings in epilepsy drug discovery at the 36th annual meeting of the Society for Neuroscience in Atlanta, Georgia. Dr. Geoff Stilwell, senior scientist at Cambria, presented a poster describing a novel screening method for antiepileptic drugs that utilizes a powerful genetic model organism, the fruit fly, Drosophila melanogaster.
